Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Albelin is a combination oral cough syrup developed and manufactured by Alben Health Care Industries. It is primarily indicated for the relief of cough associated with bronchospasm and thick mucus, common in conditions such as bronchitis, bronchial asthma, and chronic obstructive pulmonary disease (COPD). The formulation contains four active components: **ambroxol**, a mucolytic agent that reduces the viscosity of respiratory secretions; **terbutaline**, a selective beta-2 adrenergic agonist that acts as a bronchodilator to relax airway smooth muscle; **guaifenesin**, an expectorant that increases the volume and reduces the stickiness of airway secretions to facilitate their removal; and **menthol**, which provides a cooling sensation and mild local anesthetic effect to soothe throat irritation. This multi-ingredient approach effectively addresses both airway constriction and the accumulation of viscous mucus, improving respiratory comfort and clearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Albelin.